STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

TECH BIO-TECHNE CORPORATION StockScouter® Report

3

StockScouter® Score

BIO-TECHNE CORPORATION, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Shares are under accumulation by financial institutions. Marginally positive for large companies like TECH

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • The ratio of TECH’s forward price-to-earnings multiple to its estimated growth rate is well above the average of comparably-sized companies in the StockScouter universe. Negative
  • One or more analysts has modestly decreased quarterly earnings estimates for TECH. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 20% done.
Progress: 60% done.
Low
High

Core Model Grades

D
C
F
D

Previous Ratings

5
4
6